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Background: Among the multiple conservative modalities, physiotherapy is a commonly utilized treatment modality
in managing chronic non-specific spinal pain. Despite the scientific progresses with regard to pain and motor control
neuroscience, treatment of chronic spinal pain (CSP) often tends to stick to a peripheral biomechanical model, without
targeting brain mechanisms. With a view to enhance clinical efficacy of existing physiotherapeutic treatments for CSP,
the development of clinical strategies targeted at ‘training the brain’ is to be pursued. Promising proof-of-principle
results have been reported for the effectiveness of a modern neuroscience approach to CSP when compared to usual
care, but confirmation is required in a larger, multi-center trial with appropriate evidence-based control intervention
and long-term follow-up.
The aim of this study is to assess the effectiveness of a modern neuroscience approach, compared to usual care
evidence-based physiotherapy, for reducing pain and improving functioning in patients with CSP. A secondary
objective entails examining the effectiveness of the modern neuroscience approach versus usual care physiotherapy for
normalizing brain gray matter in patients with CSP.
Methods/Design: The study is a multi-center, triple-blind, two-arm (1:1) randomized clinical trial with 1-year follow-up.
120 CSP patients will be randomly allocated to either the experimental (receiving pain neuroscience education followed
by cognition-targeted motor control training) or the control group (receiving usual care physiotherapy), each comprising
of 3 months treatment. The main outcome measures are pain (including symptoms and indices of central sensitization)
and self-reported disability. Secondary outcome measures include brain gray matter structure, motor control, muscle
properties, and psychosocial correlates. Clinical assessment and brain imaging will be performed at baseline,
post-treatment and at 1-year follow-up. Web-based questionnaires will be completed at baseline, after the first 3
treatment sessions, post-treatment, and at 6 and 12-months follow-up.
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Discussion: Findings may provide empirical evidence on: (1) the effectiveness of a modern neuroscience
approach to CSP for reducing pain and improving functioning, (2) the effectiveness of a modern neuroscience
approach for normalizing brain gray matter in CSP patients, and (3) factors associated with therapy success.
Hence, this trial might contribute towards refining guidelines for good clinical practice and might be used as a
basis for health authorities’ recommendations.
Trial registration: ClinicalTrials.gov Identifier: NCT02098005.
Keywords: Chronic pain, Low back pain, Neck pain, Education, Exercise, Motor control, Neuroscience,
Randomized controlled trialBackground
Chronic spinal pain (CSP) is a major public health
problem worldwide as it is a common disorder and a
major cause of disability and health care utilization
[1-4]. Taking chronic non-specific low back pain as an
example, best estimates suggest that its prevalence is
about 23% with 11-12% of the population being dis-
abled by it [2,5]. According to the Global Burden of
Disease Study 2010 [4], low back pain contributes 83.1
million years lived with disability (i.e., 10.7% of total
years lived with disability), thereby being the leading
cause of years lived with disability. From an economic
perspective, the group of chronic, disabling patients is
responsible for the bulk of low back pain care resource
consumption, denoting considerable costs [6,7]. No
wonder, then, that research on the most effective and
affordable strategies to deal with CSP has been strongly
advocated [1-3,8].
Management of CSP should aim at achieving and
maintaining a clinically important reduction in pain and
disability with a minimum amount of costs and inconve-
niences related to the intervention [2,9]. For CSP, most
clinical practice guidelines agree on the use of brief
education about the problem, recommendations to stay ac-
tive, adjunctive analgesics, non-steroidal anti-inflammatory
drugs, weak opioids (short-term use), exercise therapy (of
any sort), spinal manipulation, multidisciplinary re-
habilitation, cognitive behavioral therapy, and strong
opioids [2,5,10,11]. Systematic reviews of the most
commonly applied treatments for CSP in primary care
generally reach similar conclusions: most treatments
provide small, short-term benefits when compared to
no or sham treatment, but offer little benefit when
compared to other forms of intervention [8,12-18]. In
an attempt to account for the equivalence in outcome
of very disparate treatments, Wand and O’Connell [19]
suggested that distinct treatments might show similar
effectiveness because they could all work through the
same mechanism, e.g. by affecting higher neurological
levels. As such, one could hypothesize that greater
effect sizes may be observed if treatment strategies
would focus more on central processes [2,19].In non-specific CSP, there is increasing evidence for
supraspinal abnormalities (i.e., distinct brain activity and
morphology, hyperexcitability of the central nervous
system and central sensitization) in addition to the com-
pelling evidence for impaired motor control of spinal
muscles (reviewed elsewhere [19-24]). As such, the de-
velopment of novel clinical strategies targeting at nor-
malizing neurological processing (“training the brain”) to
achieve pain reduction and improved function has been
argued to be a challenging new direction for musculoskel-
etal clinicians and researchers involved in the management
of CSP. Still, at present, physiotherapy for patients with
CSP is often based either on a pure biomedical (e.g.
neuromuscular training) or psychosocial model (e.g.
graded exposure in vivo, graded activity, multidiscip-
linary pain treatment). Yet neither approaches account
for our current understanding of modern pain neuro-
science. Therefore, the theoretical rationale for com-
bining both approaches in a program that addresses
central nervous system dysfunctions (e.g. dysfunctional
endogenous analgesia [25], central hyperexcitability
[26]), psychosocial factors (e.g. pain catastrophizing
[22] and illness perceptions [27]) as well as peripheral
dysfunctions (impaired motor control of spinal mus-
cles) in a broader biopsychosocially-driven framework
has been elaborated in a recent perspective paper of
our research group [22].
Addressing the proof-of-concept, 1 single case study
[28] and 2 small-scale single-centered randomized con-
trolled trials [29,30] support the clinical effectiveness
(large effect size and small numbers needed to treat) of
the modern neuroscience approach to CSP (i.e., pain
neuroscience education followed by cognition-targeted
motor control training) compared to usual care in terms
of pain reduction and improved function, and suggest
that side effects are not to be expected. However, these
pilot studies comprised relatively small populations of
low back pain patients who were treated with the mod-
ern neuroscience approach and follow-up after 1 year
was reported for less than 20 patients. In addition, these
studies were from the same research group and from 1
single treatment center. Hence, replication in a larger,
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intervention performed by researchers who are independ-
ent from the research group who generated the proof-of-
concept, is required. Preferably, such a project does not
only focus on chronic low back pain, but on CSP in
general, including non-traumatic chronic low back and
neck pain, failed back surgery and chronic whiplash as-
sociated disorders.
Previous work from our research group has shown
that therapeutic pain neuroscience education alone is
able to improve brain-orchestrated endogenous analgesia
in patients with chronic widespread pain [31]. Until
now, no brain imaging studies have evaluated whether
(and how) physiotherapy can influence brain characteris-
tics in patients with CSP. Hence, this will be the first
randomized trial examining whether a treatment tar-
geted at the brain actually does alter the brain’s charac-
teristics. In addition, the identification of major reasons
for (sub) optimal treatment success or subgroups that
benefit most can help the physician to optimize CSP
management.
Based on this background, this 12-month prospective
study has been designed in order to estimate the effective-
ness of a modern neuroscience approach in CSP patients,
its determinants and its changes during a 1-year follow-up.Objectives
Table 1 summarizes the primary and secondary objectives
of the study. The primary objectives are to investigateTable 1 Primary and secondary objectives to be investigated
Primary objectives Longitudinal phase
− Effect of a modern neuroscience approach on p
− Effect of a modern neuroscience approach on in
tresholds (PPTs) and conditioned pain modulatio
− Effect of a modern neuroscience approach on fu
Secondary objectives Cross-sectional phase (baseline)
− Relation between brain gray matter structure (co
− Relation between brain gray matter structure (co
− Relation between pain and motor control
− Associations between pain, functional disability,
Longitudinal phase
− Effect of a modern neuroscience approach on brain
− Effect of a modern neuroscience approach on m
− Relation between changes in pain, functional di
− Proportion of patients that reach therapy succes
− Factors associated with clinically important chan
− Factors associated with poor outcome following
− Mediating factors for treatment effects
CSP: chronic spinal pain.whether treatment with a modern neuroscience ap-
proach in CSP patients results in a significant decrease
in pain and disability compared to usual care evidence-
based physiotherapy.Methods/Design
Design
The present study is a 12-month multi-center, triple-blind,
randomized, controlled, parallel group trial that will be car-
ried out between February 2014 and April 2017. Patients
with CSP (including low back and neck pain, failed back
surgery and chronic whiplash associated disorders) will be
enrolled in a structured 3-month rehabilitation program
organized in 2 university hospitals in Belgium (Ghent
University Hospital and University Hospital Brussels). More
specifically, therapeutic pain neuroscience education com-
bined with cognition-targeted motor control training will
be compared to back/neck school and general exercises.
Treatment outcomes will be assessed at baseline, after
3 treatment sessions, post-treatment (at 3 months), at
6 months and 1 year follow-up (Figure 1). Following the
go/no-go principle, however, the 1-year follow-up examin-
ation will not take place in case that treatment effects are
no longer present at 6 months follow-up in none of the
treatment arms.Study population
The study population will include approximately 120 CSP
patients. Patients will be recruited by the participatingin CSP patients
ain compared to usual care evidence-based physiotherapy
dices of central pain processing (i.e. widespread cold pain, pressure pain
n) compared to usual care evidence-based physiotherapy
nctioning compared to usual care evidence-based physiotherapy
rtical thickness) and pain (including symptoms of central sensitization)
rtical thickness) and (dysfunctional) motor control
and physical/psychological correlates of pain and dysfunctioning
gray matter structure compared to usual care evidence-based physiotherapy
otor control compared to usual care evidence-based physiotherapy.
sability, and physical/psychological correlates of pain and dysfunctioning
s after 3, 6 and 12 months from cross-sectional phase visit
ges in primary outcome measures
treatment
Figure 1 Flow chart of research design. CPT: cold pressor test; CSI: Central Sensitization Inventory; IPQ-R: Illness Perception Questionnaire-Revised;
NRS: Numerical Rating Scale; PCS: Pain Catastrophizing Scale; PDI: Pain Disability Index; PPT: pressure pain threshold; PVAQ: Pain Vigilance and Awareness
Questionnaire; SF-36: medical outcomes Short Form 36 Health Service Survey; TSK: Tampa Scale for Kinesiophobia.
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pital, from primary care practices (medical doctors)
and via adverts. Dutch speaking male and female adult
(aged 18 – 65 years) patients with non-specific CSP (at
least 3 days/week) for at least 3 months, currently
seeking care for low back or neck pain, not starting
new treatments or medication and continuing usual
care 6 weeks prior to and during study participation
(to obtain a steady state), will be eligible for study
participation after signing the informed consent. Pa-
tients with neuropathic [32] or chronic widespread
pain as defined by the criteria of the 1990 ACR [33]
will be excluded. A history of back or neck surgery in
the past 3 years, a lifetime history of specific back orneck surgery (e.g. surgery for spinal stenosis) or osteo-
porotic vertebral fractures, rheumatologic diseases,
concomitant therapies (i.e., rehabilitation, alternative
medicine or therapies) and medical conditions or
contra-indications for MRI are also exclusion criteria.
Pregnant women and women given birth in the last
year before enrolment will be excluded from the study,
as are patients who live and work outside a 50-km ra-
dius of the treatment location. Study participants will
be asked to refrain from analgesics 48 h prior to assess-
ments, to abstain from caffeine, alcohol and nicotine
24 h prior to assessment, and not to undertake physical
exercise (>3 metabolic equivalents) in the 3 days before
assessment.
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After eligibility has been confirmed, patients will be in-
formed about the study comparing two physiotherapeu-
tic treatment options. After obtaining written informed
consent, baseline measurements will be performed (see
next paragraph). Participants will then be randomized to
either control or experimental group (1:1 ratio) using a
stratified permuted block allocation with stratification
factors being treatment center (Ghent or Brussels),
dominant pain location (low back or neck) and gender
(male or female) and with a block size of four [34,35].
Randomization will be done at the Biostatistics Unit
(Ghent University) by an independent investigator using
the SAS version 9.4 package. The randomization sched-
ule will be known only to 1 investigator who is not in-
volved in recruiting participants. The randomization will
be concealed from patients and the other investigators
involved in patient assessments and analyses.
Outcome measures
Pain and restrictions in functioning will be the primary out-
come measures. Secondary outcome measures will include
brain gray matter structure, motor control, muscle proper-
ties, and psychosocial factors that may interfere with pain.
Methods for assessment will include web-based question-
naires (Dutch version), clinical testing and brain imaging
using magnetic resonance imaging (MRI).
Primary outcomes
Pain, including symptoms and indices of central
sensitization, will be assessed through a self-reported web-
based questionnaire and a clinical assessment. The follow-
ing self-administered online tools will be used for pain
assessment at baseline, post-treatment, and at 6 and 12-
months follow-up:
– A Numerical Rating Scale (NRS) for pain ranging
from 0 = “no pain” to 10 = “the worst pain
imaginable” (“How would you rate your spinal pain,
on average, over the last three days?”) and an
additional enquiry about the number of health visits
for spinal pain over the course of the follow-up
period: “Since your assessment on [date of final
assessment], how many times have you consulted a
health care professional for your spinal pain?” [29],
– the Central Sensitization Inventory (CSI) [36],
comprising 2 parts: current health symptoms indicative
of central sensitization (25 statements; responses are
recorded about the frequency of each symptom, with a
Likert scale from 0 (never) to 4 (always), resulting in a
total possible score of 100; higher scores are associated
with a higher degree of self-reported symptomology)
and previously diagnosed central sensitivity syndromes
and related conditions [36],– the SF-36 (Short Form Health Survey – 36 item),
see below.
Clinical assessment of pain will comprise pressure pain
threshold (PPT) measurements and the cold pressor test
(CPT). Measurements will be taken at baseline, post-
treatment, and at 1-year follow-up.
– Pressure algometry will be used to measure PPTs at
the symptomatic levels (the upper trapezius muscle
midway between C7 and the tip of the acromion
[37] and 5 cm lateral of the spinous process of L3
[38]) and at remote sites (quadriceps muscle and the
web between thumb and index finger [39]) using a
digital Wagner algometer (Wagner Instruments,
Greenwich, CT). The rate of pressure increase will
be maintained at a constant rate of 1 kg/m2/s
[38,40]. PPTs will be tested unilaterally: the most
painful side will be assessed unless the pain is evenly
distributed on both sides. Then, the dominant side
will be investigated. At each of the selected
measuring points, the threshold will be determined
as the mean of 2 consecutive (30 s in between)
measurements [40]. By evaluating symptomatic and
remote sites, both primary and secondary
hyperalgesia can be assessed [41-43]. Algometry has
been shown to provide a reliable and valid measure
of PPTs [44].
– The CPT, a widely used and reliable test, will be
used to evaluate the efficacy of the descending
inhibitory modulation of pain (i.e. conditioned pain
modulation) [45]. The conditioning stimulus in our
diffuse noxious inhibitory control will be realized by
the immersion of the contralateral hand to the PPT
measurements (up to the wrist; see above) for
2 minutes into a tub containing 12 degrees C cold
water [46]. Before and during submersion, the PPTs
will be measured on several body sites using
pressure algometry (see above; noxious mechanical
test stimuli). Subjects will be asked to rate the
perceived pain intensity on an 11-point visual NRS
after 30 and 115 seconds.
Spinal pain related restrictions in functioning will be
assessed using self-reported web-based questionnaires:
– The social disability associated with spinal pain will
be assessed by the Pain Disability Index (PDI) [47,48],
consisting of 7 items to be rated on an 11-point NRS
(range from 0 = “no disability” to 10 = “total disability”).
The degree to which pain interferes with the perform-
ance of social roles in 7 areas will be evaluated: family/
household responsibilities, recreation, social activities,
occupation, sexual behavior, self care, and life support
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higher scores indicate more disability. Patients will
complete the PDI at baseline, after the first 3 treatment
sessions, post-treatment, at 6-month follow-up and at
1-year follow-up. Results in different chronic pain
populations indicate that the PDI is a reliable and valid
instrument [49].
– The Short Form 36 Health Status Survey (SF-36)
will be used to assess functional status and well-being
or quality of life at baseline, post-treatment, and at
6 and 12-months follow-up. The SF-36 contains 8
dimensions (physical functioning, social functioning,
physical role, emotional role, mental health, vitality,
bodily pain, and general health perceptions). The
overall value ranges from 0 to 100, with improvement
as scores increase. The psychometric properties of the
SF-36 are well-characterized in a wide variety of patient
populations [50,51].
Secondary outcomes
Brain gray matter structure
High-resolution MR scanning will be performed on a 3 T
Trio Tim magnet (Siemens medical solutions, Erlangen,
Germany) with a standard head coil. Using voxel-based
morphometry, brain gray matter structure will be investi-
gated in brain areas involved in pain processing and
motor control. MRI data will be obtained at baseline,
post-treatment, and at 1-year follow-up.
More specifically, a T1 weighted structural MRI will
be acquired by using a 3D-FLASH sequence (repetition
time 2250 ms, echo time 4.18 ms, flip angle 9°, field of
view 256 × 256; 176 slices), acquisition time 05′14″. Re-
gional gray matter density will be assessed with voxel-based
morphometry that allows for applying voxelwise statistics
to detect regional differences in gray matter volumes. Pre-
processing will involve spatial normalization, gray matter
segmentation, and 10 mm spatial smoothing with a Gauss-
ian kernel [52]. The T1-weighted images will be processed
and analyzed with FreeSurfer; cortical thickness and surface
area will be calculated.
Motor control
Motor control will be assessed by clinical measurements
of postural steadiness, habitual standing posture, spinal
range of motion, and sensorimotor control. These as-
pects will be tested at baseline, and at 3-month and 1-
year follow-ups.
Postural steadiness will be characterized by postural
sway features as measured by an AccuGait portable for-
ceplate (50 cm × 50 cm) (Advanced Medical Technol-
ogy, Inc. Watertown, MA) during bipedal standing with
eyes closed on a firm surface. Centre of pressure (COP)
data will be sampled at a frequency of 100 Hz during 3
trials of 90 s. The following COP stability parameterswill be computed: mean sway velocity, 95% confidence
ellipse area, standard deviation of sway velocity, of
medio-lateral COP data and of anterior-posterior COP
data. During these posturography measurements, sub-
jects will be barefoot and will be instructed to stand as
still as possible with arms by their sides. Test-retest
reliability of posturography is well-documented in adult
populations [53]. In addition, each subject will complete a
clinical balance test: standing in tandem stance (heel-to-
toe) with either the left or right foot in front, with eyes
open and eyes closed. Patients’ performance during a 30-
second tandem stance will be graded as pass/fail [54].
For the assessment of habitual standing posture in the
sagittal plane, the orientation of gross body segments
with respect to the vertical will be quantified using post-
hoc analyses of digitized photographs of participants.
Retro-reflective markers will first be placed on the C7
spinous process, greater trochanter, and lateral malleolus
by one trained examiner. Lateral photographs will then
be taken within a standardized photographic set-up after
each patient is asked to stand normally and relaxed,
looking straight ahead. Using ImageJ software (National
Institutes of Health, Bethesda, MD), the craniovertebral
angle will be calculated in patients with dominant neck
pain. In patients with dominant pain located in the low
back, three angular measures will be determined: trunk lean
angle, body lean angle and pelvic displacement angle. For
more detailed methods, see previous articles by Dolphens
et al. [55-57]. Furthermore, in low back pain patients,
lumbar lordosis will be measured using a skin-surface
hand-held electromechanical device, the Spinal Mouse
(Idiag; Voletswil, Switzerland). The intratester, intertester
and day-to-day reliability of this wheeled accelerometer
have been published in previous studies [55,58-60].
Range of motion of the cervical spine (flexion, extension,
lateral flexion) will be measured in neck pain patients
(seated position) using the Acumar™ digital inclinometer
(Model ACU 360, Lafayette Instrument Company,
Lafayette, IN) that is placed on the vertex of the head
through T1. According to the manufacturer’s specifica-
tions, this device is capable of measuring a range up to
180 degrees with an accuracy of ± 1 degree. In low back
pain patients, the lumbar range of motion in the sagittal
plane (flexion, extension) will be measured using the Spinal
Mouse device (see above) with patients in the standing pos-
ition. Furthermore, lumbar lateral flexion will be measured
using the Acumar™ digital inclinometer (see above) placed
on T12 through S1. For each movement direction, the
mean of three consecutive measurements will be taken.
With regard to sensorimotor control, the following
components will be assessed:
– Proprioception will be determined by evaluating the
position-reposition accuracy of the spine. In neck
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cervicocephalic relocation test to the neutral head
position with eyes closed [61]. More specifically,
patients will be seated on a stool without backrest
with their hands on their thighs, and hips and knees
bent 90 degrees. After an active submaximal range
cervical flexion-extension and right and left rotation,
patients will be instructed to relocate back to the
neutral position. Absolute and relative errors will be
expressed in degrees [62]. In low back pain patients,
position-reposition accuracy will be assessed both in
the sitting and standing position [63]. First, the
tester will place the subject in a neutral lumbar
spine position [63]. Then, after having performed
three pelvic rotations (anterior and posterior pelvic
rotation), the subject will be asked to reassume the
reference position as accurately as possible. Assessment
will be based on a clinical rating scale (unpublished
results) evaluating the position-reposition accuracy to
the neutral lumbar spine and pelvis position, and
deviations in adjacent regions (thoracic kyphosis, trunk
inclination, antero-posterior translation of the pelvis
with respect to the feet (in standing position only),
degree of knee flexion (in standing position only))
compared to the initial, neutral position. Each
position-reposition cycle will be performed once.
– Neuromuscular control will be assessed as the
patients’ ability to perform the skill of activation of
specific, deep stabilizing muscles for which there is
scientific evidence that they play a crucial role in
spinal stability. In neck pain patients, the
contraction of the deep neck flexors will be
evaluated through the craniocervical flexion test
[64], and the lower and middle trapezius muscles
will be assessed via the scapular holding test/scapula
setting [65]. More specifically, assessment of
contraction of the deep neck flexors will be scored
based on the output obtained via an air-filled
pressure sensor (Stabilizer, mmHg), substitution
of superficial muscles, movement pattern and the
holding capacity. Analogously, performance of the
neuromuscular control of the scapulothopracic
muscles will be based on the quality of contraction,
substitution, movement pattern, and ability to maintain
contraction as scored on a clinical rating scale
(unpublished results). In low back pain patients,
multifidus and transverse abdominis contraction
will be evaluated in prone and supine (drawing-in
action), respectively. Performance will be scored
using a clinical rating scale based on the quality of
contraction, substitution of superficial muscles,
symmetry of contraction and the holding capacity.
– Movement control of the lumbar spine will be
assessed in low back pain patients. A set of 6dissociation tests that have shown substantial
reliability [k > 0.6] [66] will be included: 1) waiters
bow (flexion of the hips in upright standing position
without movement (flexion) of the low back); 2)
pelvic tilt (active dorsal tilt of the pelvis in upright
standing); 3) one leg stance (from normal standing
to one leg stance: measurement of lateral movement
of the belly button); 4) sitting knee extension
(upright sitting with neutral lumbar lordosis;
extension of the knee without movement (flexion) of
low back); 5) rocking forward/backward (quadruped
position). Starting position 90° hip flexion. Transfer
of the pelvis backwards and forwards (“rocking”)
keeping low back in neutral; 6) prone knee flexion
(prone lying, active knee flexion). The order of the
tests will be standardized. A strict protocol to
instruct the tests and to rate test performances as
“correct” or “incorrect” will be applied as described
by Luomajoki et al. [66], resulting in an overall score
between 0 and 6. No movement control test will be
performed in neck pain patients.
– Low back pain patients will perform a lumbopelvic
control test in the sitting and standing position. A
clinical rating scale (article submitted for
publication) comprising the quality of the
lumbopelvic motion, control of the adjacent areas,
preference of motion direction, breathing, and
repetitions will be used for evaluation, with higher
scores indicating better performance.
As the observers’ level of experience is important for
good test reliability, all tests will be rated by the same
experienced observer [66-69].
Muscle properties
The assessment of intrinsic muscle properties (i.e., muscle
strength and endurance) will take place at baseline, post-
treatment and at 1-year follow-up.
Isometric muscle strength will be measured with a
hand-held dynamometer (MicroFet2; Hoggan Health
Industries Inc., West Jordan, UT) with a sensitivity of
0.4 N. In neck pain patients, the testing procedure will
consist of seated isometric strength measures for neck
flexion, extension and side bending (left and right). For
each movement, the dynamometer will be placed on
specific marker points: the imaginary line through the
supra-orbital notch for flexion, the protuberance of the
occiput for extension and the temporal bone for side
bending. In patients with dominant low back pain, trunk
flexor and extensor muscle strength will be evaluated.
Trunk flexor muscle strength will be measured with the
patient in a semi-upright sitting position (45 degrees),
knees extended, arms flexed alongside the trunk, hands
placed on the homolateral shoulder, and head mid-line.
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the sternum at the centre of the chest. Trunk extensor
muscle strength will be measured with the subject in
prone, hands underneath the forehead and head mid-
line. The dynamometer will be applied at the inferior
angle of the scapulae at the centre of the back. For
muscle strength tests, patients will be allowed 1 warm-
up trial, followed by 3 successive maximal effort trials
separated by 10-s rest periods. Patients will be asked to
take 1 or 2 s to come to maximum effort and then, 5 s
as forcefully as possible. The mean of 3 consecutive
measurements per movement will be taken.
Muscle endurance will be assessed using isometric
tests, i.e. patients will be instructed to maintain an im-
posed posture as long as possible. In neck pain patients,
endurance of the neck flexors will be evaluated with the
deep neck flexor endurance test [70,71]: patients in a su-
pine, hook-lying position will be instructed to maximally
tuck their chin, lift their head by approximately 2.5 cm
and to hold this position as long as possible. Low back
pain patients will perform a trunk flexor and extensor
endurance test. The flexor endurance test will require
subjects to hold their upper body in an unsupported,
semi-upright sitting position (45 degrees) with knees ex-
tended, arms flexed alongside the trunk, and hands placed
on the shoulders [63]. Isometric endurance of the back
muscles will be assessed using the modified Biering-
S∅rensen test [63,72,73]. For endurance tests, the position-
holding time will be recorded. Verbal encouragement will
be given by the tester during the endurance tests to ensure
that the maximal effort is produced by the patient.
Psychosocial correlates
Patients will complete a web-based online battery of
questionnaires at baseline, after 3 treatment sessions,
post-treatment, and at 6- and 12-month follow-ups. The
following standardized and reliable questionnaires (Dutch
version) will be used to measure psychological factors that
may interfere with pain:
– The Pain Catastrophizing Scale (PCS) will be
included to assess catastrophic thinking about pain.
It consists of 13 items describing different thoughts
and feelings that individuals may have when
experiencing pain. Items are scored on a 5-point
scale. A general score and scores on 3 subscales
(i.e., helplessness, magnification, and rumination)
will be obtained; higher scores indicate more severe
catastrophic thoughts about pain [74,75]. The
psychometric properties of the Dutch version of the
PCS are well established [74,76,77].
– The Pain Vigilance and Awareness Questionnaire
(PVAQ) will be used to investigate patients’
attention to pain. It is a 16-item measure ofattention to pain that assesses awareness,
consciousness, vigilance, and observation of pain.
Scores range from 0 to 80 and high scores correspond
to hypervigilance for pain. The items have demonstrated
good internal consistency (Cronbach’s alpha = .86) in
a population of chronic low back pain patients [78].
– The Tampa Scale for Kinesiophobia (TSK) is a 17-item
questionnaire that will be used to measure the fear of
(re) injury due to movement [79,80]. Scores range
from 17 to 68, with scores ≤ 37 suggesting low fear of
movement and scores > 37 indicating high fear of
movement. The TSK-Dutch version that will be used
in this study is shown reliable and valid [74,80-82].
– The Illness Perception Questionnaire-Revised
(IPQ-R), consisting of 3 domains, will be used to
measure patients’ illness perceptions [83]. In the first
domain, called illness identity, the perceived symptoms
and their possible relation to the illness are evaluated.
In this study, participants will indicate whether or not
they believe that a specific symptom is related to spinal
pain (“yes” or “no”). The second domain, the beliefs
domain, covers 7 dimensions: the acute/chronic
timeline, the cyclical character of the illness, the
consequences, controllability, curability, emotional
representations and illness coherence. The third
domain lists 18 possible causes to which individuals
attribute their condition, the degree to which
individuals perceive themselves as responsible for
the illness, as well as the responsibility individuals
take for curing themselves. For each item in the
second and third domain, patients rate their level
of agreement on a 5-point Likert scale, ranging
from “strongly disagree” to “strongly agree” [83].
Studies have shown that both the English and
Dutch versions of the IPQ-R have excellent validity
and reliability [84,85].Interventions
Before starting the study, physiotherapists involved in
the treatment will be trained extensively by expert thera-
pists in the domain. They will also receive a manual con-
taining descriptions of procedures and checklists. Using
a therapists’ treatment diary, therapy will be monitored
and evaluated.
Within a 12-week period, patients in each group will
receive 18 treatment sessions from their trained physio-
therapist. In both groups, the first 3 sessions (spread
over 2 weeks) will consist of education, whereas the next
15 sessions (spread over the next 10 weeks) will be exer-
cise according to the protocol. All sessions are one-on-
one sessions lasting about 30 minutes, except for session
1 (group session, maximum 6 persons/group, 1 hour)
and session 2 (online module performed at home).
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(explanation by the therapist) and visually (summaries,
pictures, and diagrams on computer). After the first ses-
sion, patients will also receive an information leaflet
about the education according to the protocol and will
be asked to read it carefully. Although initiated during
the first 3 sessions, education will be ongoing through-
out exercise therapy. In addition to the individually
tailored exercises performed in physiotherapy, a home
exercise program will be established for each patient.
For home exercises, modalities and clear verbal, written
and visual instructions will be given. Patients will be
strongly encouraged to continue these exercises during
the follow-up year.
Modern neuroscience group
The modern neuroscience approach will entail therapeutic
pain neuroscience education followed by cognition-targeted
motor control training. Pain neuroscience education will be
applied to reconceptualize pain and to convince the pa-
tients that all pain is in the brain, and that hypersensitivity
of the central nervous system rather than local tissue
damage may be the cause of their symptoms. The edu-
cation will cover the physiology of the nervous system
in general and of the pain system in particular. The
content and pictures of the educational sessions are
based on the book “Explain Pain” [86] and have been
used in earlier pilot studies [29,30,87,88].
In the present study, the Dutch Neurophysiology of
Pain Test (patient version) [89] will be used as part of
the intervention to ascertain the quality of the education
program: after the third session, patients will be asked to
fill out this valid and reliable questionnaire to assess
their knowledge on pain neurophysiology [89,90]. 90% of
the patients should pass the test (desired mean score of
65%). Patients’ misinterpretations will be discussed fur-
ther upon completion of the questionnaire.
As such, therapeutic pain neuroscience education (or
rather “communication”) will prepare the patients for a
time-contingent, cognition-targeted approach to daily
(physical) activity and exercise therapy. Once adaptive
beliefs are acquired regarding CSP, the exercise therapy
with specific emphasis on spinal motor control training
will be initiated (session 4). This training will consist of
sensorimotor control training by facilitating the proprio-
ceptive system and optimizing the coordinative muscle
recruitment patterns [68,91-93]. However, some modifi-
cations will be made to the original motor control pro-
gram to comply with modern pain neuroscience (i.e.,
cognition-targeted motor control training detailed in
[22,30]). In neck pain patients, this phase of the exercise
will involve retraining of the deep cervical flexors/exten-
sors and scapular muscles, whereas retraining of the
deep muscles surrounding the lumbopelvic region (e.g.,multifidus, transversus abdominis, psoas, pelvic floor mus-
cles) will be performed in patients with low back pain.
Progression to a next level of (more difficult) dynamic and
functional exercises will be preceded by an intermediate
phase of motor imagery [22,30].
A time-contingent progression will be used to inte-
grate exercises with increasing complexity. In order to
maximize transfer to daily situations, late-stage progres-
sion will not only involve exercising during physically
demanding tasks, but also exposure to the feared move-
ments or activities, and exercising during cognitively and
psychosocially stressful conditions [22,30]. Throughout
the cognition-targeted motor control training program,
patients’ cognitions and perceptions about their problem
and about exercises will be addressed.
Further details of the modern neuroscience approach to
CSP, including practice guidelines, were presented previ-
ously [22,94,95].Control group
Those in the control group will receive traditional back/
neck school, including back care education and general
exercises. Back care education will cover anatomy and
biomechanics of the spine, common causes of spinal
pain, the load-tolerance model, nociceptive pain process-
ing, and ergonomic counseling based on the inherent
postural strain associated with various postures and daily
activities (including standing, sitting, and lifting). As
such, the education sessions will prepare the patients for
a symptom-contingent, biomedical approach to daily
(physical) activity and exercise therapy. In session 4, the
general exercise therapy will be started with specific em-
phasis on treating dysfunctional muscles and joints. Differ-
ent therapeutic goals will be pursued (e.g. microcirculation,
mobility, endurance, strength) depending on what emerges
from the clinical reasoning as the most dominant periph-
eral dysfunction. Importantly, abdominal and paraspinal
muscles will be targeted without involvement of deep
muscle activation. The program will also involve aerobic fit-
ness improving exercises. The progressive exercise program
will mainly entail an increase in exercise intensity, and an
evolution towards functional activities and more physically
demanding tasks while keeping the spine in physiological
neutral positions to minimize strain imposed upon the
spinal structures. All exercises will be performed in a
symptom-contingent way.Main treatment contrast
The main difference between the 2 groups is the treat-
ment of cognitive aspects of pain in the modern neuro-
science group (biopsychosocial approach), which will not
be applied in the control group (biomedical approach,
symptom-contingent treatment).
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Sample size calculations were performed with G*Power
3.1.3 (Düsseldorf, Germany) based on the therapy effects
on pain in the pilot study of Moseley [29], and account-
ing for a 30% loss to follow-up after 1 year. Calculations
were based on one-tailed testing with alpha set at 0.01
and a desired power of 0.95. Allocation ratio (N2/N1)
was defined as 1, resulting in 60 patients in the experi-
mental group and 60 in the control group.Data analysis
Data analysis will be performed using SPSS for Windows
(version 22, SPSS Inc; Chicago, IL), or the newest avail-
able version, under the intention-to-treat-principle.
Baseline data will be analyzed in order to determine
descriptive statistics for the different outcome mea-
sures for the complete CSP group. Comparability of
the groups before the intervention will be studied with
the Fisher exact test and independent samples t test.
Associations between baseline parameters will be ex-
amined. Possible changes in the outcome measures in
response to the intervention will be examined between
the two groups by using repeated measures analysis of
variance with intervention serving as the between-
subjects factor and time as the within-subjects factor.
In these analyses, treatment center, dominant pain location
and gender will be entered as covariates. Regression
analyses will be used to determine predictors for therapy
success and reasons for poor therapy outcome. For all
statistical tests, the significance level will be set at 0.05.
Risk ratios and their 95% confidence intervals will be
calculated as are effect sizes [96]. The number needed
to treat and its 95% confidence interval will be calcu-
lated for the outcomes in which a beneficial effect of
the experimental treatment is achieved. In case of ad-
verse effects, the number needed to harm and its 95%
confidence will also be calculated.Blinding
The present study is a triple-blind randomized con-
trolled trial. The patient, assessor and outcomes assessor
will be blind to the treatment groups. To keep patients
unaware of any expected treatment group benefit, pa-
tients will be informed that the effect of 2 well-
established therapies is to be evaluated. An independent
and blinded assessor will perform the baseline and
follow-up assessments. Statistical analysis will be blinded
regarding treatment group code. The researcher who
will perform the statistical analyses will not be involved
in taking the measurements. The treating physiothera-
pists will be blinded to the results of the measurements
and questionnaires.Ethics
This trial will be conducted in compliance with the
Declaration of Helsinki (1964 and amendments) and
Good Clinical Practices. Patients will give their written in-
formed consent prior to the start of any study-related pro-
cedure. Approval to conduct this study was granted by the
Ethics Committee of the Ghent University Hospital and the
University Hospital Brussels.
Results
Inclusion of patients began in February 2014 and is expected
to last until March 2016. Results are expected in 2017.
Discussion
The aim of this study is to compare usual care physio-
therapy and a modern neuroscience approach in CSP
patients. The main study question is which of the 2
treatment strategies is more effective in reducing pain
and disability associated with CSP, both in the short and
long term (1-year follow-up). Further objectives are: to
evaluate the effect on brain gray matter structure, the
factors associated with therapy success, the relationships
between (changes in) outcome parameters being pain,
disability, brain structure, motor control, muscle proper-
ties and psychosocial correlates.
With the inclusion of 120 patients with CSP, this will
be the largest study to investigate the effectiveness of 2
well-founded physiotherapy treatment strategies for pa-
tients with CSP. Furthermore, the multi-center design of
the study increases the external validity of the study
findings as it implies treatment by different physiothera-
pists in different settings and a large geographical area
for patient recruitment. Importantly, the treating physio-
therapists, blinded to the results of the measurements
and questionnaires, are equally instructed and experienced
in applying the respective treatments. Randomization
is organized centrally by the Biostatistics Unit and the
randomization schedule is only known to 1 investiga-
tor who is not involved in recruiting patients. The pa-
tients, assessors performing the baseline and follow-up
evaluations and the researcher performing statistical
analyses are blinded to group allocation. Hence, the
study is designed in a way that minimizes potential
biases.
It is expected that this randomized controlled trial will
provide novel data on the effectiveness of a modern neuro-
science approach when compared to usual care physiother-
apy on key patient-centered outcome measures (i.e., pain
and disability). These results will also contribute to under-
standing the associations between (changes in) pain, disabil-
ity, psychosocial correlates and physical factors, including
brain structure. Moreover, the study will provide insights
into major factors associated with (sub) optimal treatment
success. As such, this 12-month prospective trial may
Dolphens et al. BMC Musculoskeletal Disorders 2014, 15:149 Page 11 of 13
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practice and may be used as a basis for health author-
ities’ recommendations.
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